These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20107035)

  • 21. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis.
    Wendling D; Augé B; Streit G; Toussirot E; Mathieu S
    Joint Bone Spine; 2008 Jul; 75(4):510-1. PubMed ID: 18457981
    [No Abstract]   [Full Text] [Related]  

  • 22. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.
    Ramos-Casals M; Díaz-Lagares C; Khamashta MA
    Arthritis Rheum; 2009 Sep; 61(9):1281-2. PubMed ID: 19714598
    [No Abstract]   [Full Text] [Related]  

  • 23. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.
    Baek WS; Bashey A; Sheean GL
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):771. PubMed ID: 17575026
    [No Abstract]   [Full Text] [Related]  

  • 24. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).
    Armstrong DJ; McCarron MT; Wright GD
    Rheumatol Int; 2006 Jun; 26(8):771-2. PubMed ID: 16231119
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of rituximab in Felty's syndrome.
    Shipley E; Héraud A; Hennette A; Vernhes JP
    Joint Bone Spine; 2008 Oct; 75(5):621-2. PubMed ID: 18805034
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of relapsing polychondritis in the era of biological agents.
    McCarthy EM; Cunnane G
    Rheumatol Int; 2010 Apr; 30(6):827-8. PubMed ID: 20020132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
    Braun J
    Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.
    Abadoglu O; Epozturk K; Atayik E; Kaptanoglu E
    J Investig Allergol Clin Immunol; 2011; 21(4):319-21. PubMed ID: 21721382
    [No Abstract]   [Full Text] [Related]  

  • 30. Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al.
    Vital EM; Dass S; Buch MH; Rawstron AC; Ponchel F; McGonagle D; Emery P
    Arthritis Rheum; 2009 Jun; 60(6):1867; author reply 1867-8. PubMed ID: 19479853
    [No Abstract]   [Full Text] [Related]  

  • 31. Juvenile spondyloarthropathies and related arthritis.
    Bukulmez H; Colbert RA
    Curr Opin Rheumatol; 2002 Sep; 14(5):531-5. PubMed ID: 12192250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B cell strategy to maintain remission in ANCA-associated vasculitides?
    Adler S; Villiger PM
    J Rheumatol; 2012 Jan; 39(1):4-5. PubMed ID: 22210675
    [No Abstract]   [Full Text] [Related]  

  • 33. [Rituximab treatment of rheumatoid arthritis: new evidence].
    Nasonov EL
    Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idiopathic orbital inflammatory disease successfully treated with rituximab.
    Schafranski MD
    Clin Rheumatol; 2009 Feb; 28(2):225-6. PubMed ID: 19015801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.
    Ramos-Casals M; Soto MJ; Cuadrado MJ; Khamashta MA
    Lupus; 2009 Aug; 18(9):767-76. PubMed ID: 19578100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.
    Mekinian A; Ravaud P; Larroche C; Hachulla E; Gombert B; Blanchard-Delaunay C; Cantagrel A; Fain O; Sibilia J; Gottenberg JE; Mariette X;
    Clin Exp Rheumatol; 2012; 30(2):208-12. PubMed ID: 22341206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic therapies in autoimmune diseases.
    Penn H
    Clin Med (Lond); 2006; 6(1):105-8. PubMed ID: 16521366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of "refractory" lupus erythematosus profundus responsive to rituximab [case report].
    McArdle A; Baker JF
    Clin Rheumatol; 2009 Jun; 28(6):745-6. PubMed ID: 19343472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.